

NOVADISCOVERY

Bio & Health (Biotech - Medtech - e/m-Health - Pharma)



One line pitch:

Novadiscovary ambitions to develop a best-in-class drug discovery engine in the field of immuno-oncology based on a proprietary computational biology simulation platform.

Market Analysis:

Novadiscovary ambitions to develop a best-in-class drug discovery engine applied to the field of immuno-oncology (IO) based on a proprietary computational biology modeling & simulation framework. The company will deploy this platform into a highly-scalable IP factory based on a patented approach to predict real-world patient outcomes for new therapies. The company's 5-year development plan consists in applying its proprietary drug efficacy prediction technology to generate oncology assets in the form of new targets, repurposed drugs and combinations. The systematic exploitation of its library of computational models of cancers is expected to generate significant upside through the licensing out of early-stage assets to large pharmaceutical companies.

Business Proposition:

Novadiscovary's long-term ambition is to deploy its best-in-class drug discovery engine into a highly-scalable IP factory based on a patented approach to predict real-world patient outcomes for new therapies. Offering Nova will exploit its library of multi-scale computational models in cancer to generate assets in the form of new targets, repurposed drugs and combinations. These assets will be monetized through direct licensing deals with major IO players (BMS, AZ, Roche, etc.) or joint ventures bringing together pharmas and venture capital funds around asset-centric vehicles to move R&D programs forward.

Competitive Advantage:

Novadiscovary's competitive advantage over conventional biotechs centers on 3 key features: costs, scale, speed to proof of commercial relevance. One of the benefits of predictive computational modeling is to enable the fast and cheap exploration of a large number of hypotheses. Computer simulation enables the large-scale exploration of new drugs on a large number of indications across therapeutic areas. Finally, the Effect Model proprietary framework, by gaining acceptance with regulators and payers as a method to predict real-world outcomes, enables the upstream evaluation of a new drug's absolute and comparative efficacy. IP assets generated through Nova's platform will embed factual data to support future pricing and reimbursement negotiations for licensees.

Investment Attractiveness:

By upholding conventional new drug discovery through computational approaches, Nova ambitions to deliver on a strong value proposition: build an IP factory combining scalability, an attractive risk/return profile and unparalleled optionality for institutional investors in terms of exit scenarios.

IP Situation:

The company has protected its Effect Model methodology and associated Standard Operating Procedures with a method of use patent filed as a US priority filing in April 2010. The patent has entered national registration phases in 2013 (EU, India, China, etc.). It has yet to be formally granted by the US. By the time the IP factory churns out new assets, Novadiscovary will file corresponding composition of matter and/or method of use patents to protect its rights before they are transferred to licensees or contributed into an asset company.

COMPANY PROFILE

- **Website:**
www.novadiscovary.com
- **Contact:**
BOISSEL Francois-Henri
francois.boissel@novadiscovary.com
- **Location:**
60 AVENUE ROCKEFELLER
69008 LYON
France
- **Founded in:** 20/04/2010
- **Employees:** 10
- **Management:**
- **Financial information (€):**
 - **Company stage:**
Transition from startup to scale-up
 - **Capital raised to date:**
€1ml
 - **Monthly burn rate:**
€40k
 - **Capital seeking and date:**
€5ml by mid-2016
- **Investors:**
- **Referred by:**
Didier HOCH